Cancer metabolism: Addicted to serine.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Cancer cells are biosynthetic factories that gear multiple metabolic pathways toward cell growth and proliferation. Serine is the metabolite consumed third most by cancer cells, after glucose and glutamine, and is used as a building block for proteins and as a carbon donor for nucleotide biosynthesis. Serine can also be synthesized de novo from glucose (Fig. 1, left). Studies in the late 1980s demonstrated that de novo synthesis of serine is increased in cancer cells, suggesting that this pathway might be relevant for their growth. But it was not until the landmark discovery thatphosphoglycerate dehydrogenase (encoded by PHGDH), the first step of de novo serine synthesis, is genomically amplified in breast cancer and melanoma that this pathway came into the limelight. Importantly, silencing PHGDH in PHGDH-dependent cancers significantly affects their growth, making this enzyme an excellent target for cancer therapy. Recent work from Mullarky et al. reported the discovery of a novel noncompetitive inhibitor of PHGDH. However, although this compound was selective against PHGDH-dependent melanoma and breast cancer cell lines, it was unstable in mouse plasma, limiting its use in vivo. In this issue of Nature Chemical Biology, Pacold et al. report the discovery of small-molecule inhibitors of PHGDH that exhibit potent antitumor activity both in vitro an in vivo.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1552-4469
Volume Title
Publisher
Publisher DOI
Sponsorship
Medical Research Council (MC_UU_12022/6)